SCHEMBL4028152 — predicted protein targets

Predicted protein targets (top 19)

	gene	UniProt	supporting neighbours	confidence
▸	MAPK1	P28482	1/20	0.58

▸	SIRT2	Q8IXJ6	1/20	0.57

▸	NR1H4	Q96RI1	1/20	0.55

▸	PDK1	Q15118	1/20	0.55

▸	PDK2	Q15119	1/20	0.55

▸	PDK3	Q15120	1/20	0.55

▸	PDK4	Q16654	1/20	0.55

▸	F10	P00742	2/20	0.55

▸	MAOB	P27338	1/20	0.54

▸	LTA4H	P09960	1/20	0.54

▸	F2	P00734	5/20	0.54

▸	CTSV	O60911	1/20	0.53

▸	CTSL	P07711	1/20	0.53

▸	MEN1	O00255	1/20	0.53

▸	KMT2A	Q03164	1/20	0.53

▸	LMNA	P02545	1/20	0.53

▸	CYP4F2	P78329	1/20	0.51

▸	CYP4A11	Q02928	1/20	0.51

▸	BCHE	P06276	1/20	0.51

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compound	similarity	top predicted	shared targets
Nitric Acid SCHEMBL7234968	0.91	SIRT2 (0.53)	MAPK1SIRT2NR1H4PDK1PDK2
Nitric Acid SCHEMBL7234959	0.91	SIRT2 (0.53)	MAPK1SIRT2NR1H4PDK1PDK2
SCHEMBL4981980	0.88	NR1H4 (0.58)	MAPK1SIRT2NR1H4PDK1PDK2
SCHEMBL8119011	0.85	SIRT2 (0.64)	MAPK1SIRT2NR1H4PDK1PDK2
SCHEMBL3424427	0.85	KMT2A (0.58)	MAPK1SIRT2NR1H4PDK1PDK2
SCHEMBL4987199	0.83	LTA4H (0.66)	LTA4HMEN1KMT2A
SCHEMBL4984259	0.83	MEN1 (0.61)	NR1H4PDK1PDK2PDK3PDK4
SCHEMBL5249717	0.82	NR1H4 (0.65)	MAPK1SIRT2NR1H4PDK1PDK2
Hydrochloric Acid SCHEMBL5457996	0.82	MEN1 (0.59)	NR1H4PDK1PDK2PDK3PDK4
SCHEMBL4985850	0.81	MEN1 (0.55)	MAPK1NR1H4PDK1PDK2PDK3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 43 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

Patent	Title	Assignee	Published	Priority	Filing	Country	Status
EP-1399440-B1	5-(2-AMINOPYRIMIDIN-4-YL)BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS	VERTEX PHARMA (US)	2009-06-03	—	—	EP	disclosed
US-7488727-B2	Thiazole compounds useful as inhibitors of protein kinase	VERTEX PHARMACEUTICALS INCORPORATED (US)	2009-02-10	—	—	US	disclosed
US-7488727-B2	Thiazole compounds useful as inhibitors of protein kinase	VERTEX PHARMACEUTICALS INCORPORATED (US)	2009-02-10	—	—	US	disclosed
US-7488727-B2	Thiazole compounds useful as inhibitors of protein kinase	VERTEX PHARMACEUTICALS INCORPORATED (US)	2009-02-10	—	—	US	disclosed
US-20070249645-A1	THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE	VERTEX PHARMACEUTICALS INCORPORATED	2007-10-25	—	—	US	disclosed
US-20070249645-A1	THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE	VERTEX PHARMACEUTICALS INCORPORATED	2007-10-25	—	—	US	disclosed
US-20070249645-A1	THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE	VERTEX PHARMACEUTICALS INCORPORATED	2007-10-25	—	—	US	disclosed
US-7256190-B2	Thiazole compounds useful as inhibitors of protein kinase	VERTEX PHARMACEUTICALS INCORPORATED (US)	2007-08-14	—	—	US	disclosed
US-7256190-B2	Thiazole compounds useful as inhibitors of protein kinase	VERTEX PHARMACEUTICALS INCORPORATED (US)	2007-08-14	—	—	US	disclosed
US-7256190-B2	Thiazole compounds useful as inhibitors of protein kinase	VERTEX PHARMACEUTICALS INCORPORATED (US)	2007-08-14	—	—	US	disclosed
WO-2002102800-A1	5-(2-AMINOPYRIMIDIN-4-YL) BENZISOXAZOLES AS PROTEIN KINASE INHIBITORS	VERTEX PHARMACEUTICALS INCORPORATED (US)	2002-12-27	—	—	WO	disclosed
WO-2002096905-A1	THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2002-12-05	—	—	WO	disclosed
WO-2002092573-A2	HETEROCYCLIC SUBSTITUTED PYRAZOLES AS INHIBITORS OF SRC AND OTHER PROTEIN KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2002-11-21	—	—	WO	disclosed
WO-2002083667-A2	INHIBITORS OF C-JUN N-TERMINAL KINASES (JNK) AND OTHER PROTEIN KINASES	VERTEX PHARMACEUTICALS INCORPORATED (US)	2002-10-24	—	—	WO	disclosed
EP-0961618-A4	NOVEL COMPOUNDS	SMITHKLINE BEECHAM CORP (US)	2002-07-17	—	—	EP	disclosed
US-6369068-B1	Amino substituted pyrimidine containing compounds	SMITHKLINE BEECHAM CORPORATION	2002-04-09	—	—	US	disclosed
EP-0961618-A1	NOVEL COMPOUNDS	SMITHKLINE BEECHAM CORPORATION (US)	1999-12-08	—	—	EP	disclosed
US-5869660-A	Process of preparing imidazole compounds	SMITHKLINE BEECHAM CORPORATION (US)	1999-02-09	—	—	US	disclosed
WO-1998025619-A1	NOVEL COMPOUNDS	SMITHKLINE BEECHAM CORPORATION (US)	1998-06-18	—	—	WO	disclosed
US-5739143-A	Imidazole compounds and compositions	SMITHKLINE BEECHAM CORPORATION (US)	1998-04-14	—	—	US	disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

Patent	Title	Text reads most about	Predicted target · text-rank
US-20070249645-A1	THIAZOLE COMPOUNDS USEFUL AS INHIBITORS OF PROTEIN KINASE	BTK, AURKC, GSK3B	MAPK1 685/4885SIRT2 637/4885NR1H4 3188/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.